HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares Issuance
HAVN Life Closes First Tranche Of July Financing By ABO, Details On Amendments And Debt Shares IssuanceHAVN Life完成ABO 7月第一批融资，修订细节和债务股份发行
Biotech psychedelics company HAVN Life Sciences Inc. (OTC:HAVLF) recently closed the initial tranche of its financing pact with innovative fund Alpha Blue Ocean ("ABO"), previously announced on July 21, 2022.
Since its creation in 2017, ABO has executed more than $1.5 billion in financial commitments and more than 90 transactions, mostly within the life sciences sector, all around the globe.
Following the current first-tranche closing, HAVN issued to the investment fund managed by ABO "Global Corporate Finance Opportunities 17" a total $1,100,000 principal amount of senior unsecured convertible debenture as well as 189,393 common share purchase warrants for net proceeds of approximately $420,000.
The convertible debenture
风险提示：以上内容仅作为作者或者嘉宾的观点，不代表富途的任何立场，不构成与富途相关的任何投资建议。在作出任何投资决定前，投资者应根据自身情况考虑投资产品相关的风险因素，并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性，对此富途不做任何保证和承诺。